Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab

S. Valpione, C. Martinoli, P. Fava, S. Mocellin, L. G. Campana, P. Quaglino, P. F. Ferrucci, J. Pigozzo, C. Astrua, A. Testori, V. Chiarion-Sileni

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose The purpose of this study was to set up a prognostic model for the identification of survival predictors specific for melanoma patients treated with ipilimumab. Experimental design The following prospectively collected data were utilised: patient and primary tumour characteristics, relapse-free-interval, site and number of metastases, previous therapies and level of serum biomarkers (lactic dehydrogenase (LDH), C-reactive protein, β2-microglobulin, vascular endothelial growth factor (VEGF), IL2, IL6, S-100, alkaline phosphatase (ALP), transaminases, leucocyte count, lymphocytes subpopulations). A multivariate prognostic model was developed using the Cox regression model fitted to the data of 113 consecutive metastatic patients treated with ipilimumab (3 mg/kg, q3w) at Veneto Institute of Oncology (IOV). External validation was obtained using the data of 69 and 34 patients treated at European Oncology Institute (IEO) and University of Torino (UT), respectively. Results Median survival was 8.3, 4.9 and 7.1 months from first ipilimumab administration at IOV, IEO and UT, respectively. Both higher baseline levels of LDH (Hazard Ratio [HR] v = 1.36, 95% Confidence Interval [CI] 1.16-1.58, P

Original languageEnglish
Article number9537
Pages (from-to)2086-2094
Number of pages9
JournalEuropean Journal of Cancer
Volume51
Issue number14
DOIs
Publication statusPublished - Jun 27 2015

Keywords

  • Immunotherapy
  • Ipilimumab
  • Metastatic melanoma
  • Nomogram
  • Prognostic model

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab'. Together they form a unique fingerprint.

Cite this